Don’t miss the latest developments in business and finance.

Home / Content / B2B Connect / Pharma / Zydus receives US FDA approval for anti-viral drug oseltamivir

Zydus receives US FDA approval for anti-viral drug oseltamivir

The group has also received the US drug regulator's nod to market anti-bacterial drug, linezolid

Zydus receives US FDA approval for anti-viral drug oseltamivir
Premium
BS B2B Bureau Ahmedabad
Last Updated : Feb 27 2017 | 3:20 PM IST
Connect with us
Facebook IconLinkedIN Icon
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the US Food & Drug Administration (FDA) to market oseltamivir phosphate capsule in strengths of 30 mg, 45 mg and 75 mg. The drug, an anti-viral used in the prevention and treatment of influenza virus infection, will be produced at the Nesher Pharmaceuticals manufacturing facility located in St. Louis (Missouri, USA). 

As per IMS December 2016 (MAT), the estimated sales for oseltamivir phosphate capsule is $382 million.

The group has also received the final approval from the USFDA to market linezolid tablet (600 mg). The drug is an anti-bacterial agent used to treat certain serious bacterial infections and will be produced at the group’s formulations manufacturing facility at the pharma SEZ in Ahmedabad.

The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. 

Connect with us on WhatsApp

Also Read

After chikungunya, Zydus to now co-develop malaria drug

Zydus plans to launch ulcer drug mesalamine in US by March 2020

Zydus settles patent litigation for cholesterol lowering drug with Kowa

Zydus Cadila enters $8-bn US specialty pain market by buying Sentynl

Zydus Cadila receives US FDA nod for anti-fungal drug fluconazole tablet

First Published: Feb 27 2017 | 3:15 PM IST

Explore News